丙型肝炎病毒感染的癌症患者中基于索非布韦的治疗:一项前瞻性观察性研究
该前瞻性观察性研究纳入2014—2017年在本中心接受基于索非布韦治疗(SOFBT)的153例HCV感染癌症患者,评估SVR12、癌症相关结局与不良事件。总体SVR12为91%(128/141),不良事件以1—2级为主(90%)。
要点
- 总体SVR12为91%(128/141)。
- 32例因HCV被排除于癌症临床试验者中,27例(84%)在开始SOFBT后获得癌症治疗机会。
- 6例惰性非霍奇金淋巴瘤患者未接受癌症治疗仅用SOFBT,2例完全缓解、1例部分缓解、2例稳定。
核心结论
- 作者认为SOFBT在HCV感染癌症患者中有效且安全,可能使患者获得研究性癌症治疗的机会,可能诱导NHL缓解,并可使用8周疗程。
研究设计与样本
- 前瞻性观察性研究,纳入2014—2017年在本中心接受基于索非布韦治疗(SOFBT)的患者,共153例。
主要发现
- 153例中男性109例(71%)、白人92例(60%)、无肝硬化105例(69%)、HCV基因1型110例(72%)。
- 最常见癌症为肝细胞癌(27例,18%)和多发性骨髓瘤(14例,9%)。
- 总体SVR12为91%(128/141);接受来迪派韦/索非布韦8周治疗者SVR12为100%。
- 32例因HCV最初被排除于癌症临床试验的患者中,27例(84%)在开始SOFBT后获得癌症治疗机会。
- 6例惰性非霍奇金淋巴瘤(NHL)患者未接受癌症治疗仅用SOFBT:2例完全缓解、1例部分缓解、2例癌症稳定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data are sparse on treatment of chronic hepatitis C virus (HCV) in cancer patients. We evaluated the efficacy and safety of sofosbuvir-based therapy (SOFBT) in cancer patients. METHODS: Patients treated with SOFBT at our center during 2014-2017 were included in a prospective observational study. Efficacy [sustained virologic response at 12 weeks after the end of treatment (SVR12)], cancer-related outcomes and adverse events (AEs) were assessed. RESULTS: We included 153 patients. Most were men (109; 71%), white (92; 60%), non-cirrhotic (105; 69%), and with HCV genotype 1 (110; 72%). The most common cancers were hepatocellular carcinoma (HCC) (27; 18%) and multiple myeloma (14; 9%). The overall SVR12 rate was 91% (128/141). SVR12 was 100% in patients treated with ledipasvir/sofosbuvir for 8 weeks. Of the 32 patients initially excluded from cancer clinical trials because of HCV, 27 (84%) were granted cancer therapy access after starting SOFBT. Six patients with indolent non-Hodgkin's lymphoma (NHL) received SOFBT without cancer treatment. Two achieved complete remission, one had partial remission, and two had stable cancer. Within 6 months after SOFBT, 5% (6/121) of patients in remission or with stable cancer, had progression or recurrence (two with HCC and one each with esophageal cancer, cholangiocarcinoma, NHL, and tonsillar cancer). No de novo HCCs occurred. AEs were most commonly grade 1-2 (90%). CONCLUSIONS: SOFBT in HCV-infected cancer patients is effective and safe, may permit access to investigational cancer therapy expanding treatment options, may induce remission of NHL, and may be used for 8 weeks.
引用
- Torres HA, Economides MP, Angelidakis G, et al. Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol. 2019. PMID: 30410039. doi:10.1038/s41395-018-0383-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。